We are live on ! Find out more
SRPT icon

Sarepta Therapeutics

377 hedge funds and large institutions have $8.66B invested in Sarepta Therapeutics in 2022 Q3 according to their latest regulatory filings, with 79 funds opening new positions, 121 increasing their positions, 116 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more first-time investments, than exits

New positions opened: 79 | Existing positions closed: 37

68% more call options, than puts

Call options by funds: $269M | Put options by funds: $160M

58% more capital inflows, than outflows

Capital inflows: $1.37B | Capital outflows: $863M

14% more funds holding

Funds holding: 332 → 377 (+45)

11% more funds holding in top 10

Funds holding in top 10: 9 → 10 (+1)

5.57% more ownership

Funds ownership: 83.85% → 89.43% (+5.6%)

4% more repeat investments, than reductions

Existing positions increased: 121 | Existing positions reduced: 116

Holders
377
Holders Change
+45
Holders Change %
+13.55%
% of All Funds
6.46%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.17%
New
79
Increased
121
Reduced
116
Closed
37
Calls
$269​M
Puts
$160​M
Net Calls
+$109​M
Net Calls Change
+$63.8​M

SRPT Hedge Fund Activity: Q3 2022 in Review

377 of the 5,833 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2022, worth a combined $8.66B — up 57% from $5.5B a quarter earlier.

Buyers outnumbered sellers: 79 funds opened new SRPT positions and 37 closed out — a net gain of 42 holders — while 121 added to existing stakes and 116 trimmed.

The largest buyer was Avidity Partners Management, opening a new position worth an estimated $95.6M. The largest seller was Sands Capital Management, cutting an estimated $124M.

  • 377 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2022, up from 332 in Q2 2022.
  • Funds reported $8.66B of Sarepta Therapeutics stock for Q3 2022, up 57% quarter-over-quarter.
  • 79 funds opened new Sarepta Therapeutics positions in Q3 2022 and 37 closed out, a net change of +42 holders.
  • The largest Sarepta Therapeutics buyer in Q3 2022 was Avidity Partners Management, an estimated $95.6M added.
  • The largest Sarepta Therapeutics seller in Q3 2022 was Sands Capital Management, an estimated $124M sold.

Based on aggregated 13F filings for Q3 2022.